weight loss with glp-1 agonists Medications: Everything You Need to Know Comparing Ozempic, Wegovy and Other

Alcohol, liver disease and the gut microbiota

Drucker, D

1 Introduction The advent of incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their combinations, as pharmacological treatments for obesity and type 2 diabetes, has sparked intense debate about their role relative to traditional lifestyle interventions such as exercise and dietary modification

For patients, this means navigating a more complex treatment landscape, where outcomes depend not only on the drug itself but on the system surrounding it

Further clinical evidence is needed to verify the effects of GLP-1R agonists on cognitive function and pathology in AD patients